ESMO 2025: GFH375 Shows Potential Against KRAS G12D Pancreatic Tumours

Oncogenic KRAS mutations, particularly the G12D variant, are the most common drivers of pancreatic ductal adenocarcinoma (PDAC), accounting for roughly 40% of cases and predicting a poorer prognosis. This mutation is a crucial target for new…